Monitor upcoming quarterly reports for sustained revenue growth and progress toward breakeven. The capital raise mitigates near-term liquidity concerns, but profitability remains a key risk.
Price Chart
Executive Summary
RenovoRx reported full-year 2025 revenue of $1.1 million, a significant increase from $43,000 in 2024, reflecting early commercial traction for its RenovoCath device. The company also raised $10 million in net proceeds from a private placement, boosting its cash position to $13 million. However, net loss widened to $11.2 million from $8.8 million, and EPS missed consensus by 4.3%.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $1.1 million, up from $43,000 in 2024.
- Net loss increased to $11.2 million in 2025 from $8.8 million in 2024.
- EPS of $-0.08 missed consensus of $-0.08 by 4.3%.
- Company raised $10 million in gross proceeds ($9.2 million net) in March 2026, bringing cash on hand to $13 million.
- Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026 with final data expected in 2027.
Financial Impact
Revenue grew 2,458% YoY to $1.1 million, but net loss expanded by $2.4 million. The $10 million capital raise strengthens the balance sheet.
Risk Factors
- Widening net loss despite revenue growth indicates high operating expenses.
- Reliance on future financing or revenue growth to sustain operations.
- Clinical trial delays or negative results could impact valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-013653 |
| Document: form8-k.htm | 0001493152-26-013653 |
| Document: 0001493152-26-013653-index-headers.html | 0001493152-26-013653 |
| Document: 0001493152-26-013653-index.html | 0001493152-26-013653 |
| Document: 0001493152-26-013653.txt | 0001493152-26-013653 |
| 8-K Data (Synthetic) | 0001493152-26-013653 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $1.27 | awaiting T+60 | — | $1.31 (+3.15%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.31 (+45.86%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.31 (−42.38%) |
May 26, 2026 21w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.31 (+43.01%) |
May 19, 2026 22w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.31 (+62.53%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.31 (+67.31%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.31 (+59.76%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.31 (+57.64%) |
Apr 28, 2026 25w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.31 (+55.95%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.31 (+31.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers